Stay updated on Pembrolizumab for Recurrent Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page
- Check4 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for a phase II pembrolizumab study in recurrent glioblastoma, including its design, eligibility criteria, outcomes, and history. It also includes a study protocol and statistical analysis plan.SummaryDifference52%

- Check11 days agoChange DetectedThe site footer revision label changed from v3.7.2 to v3.8.0 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA sitewide notice about NIH’s terminology transition appeared, and the site revision changed from v3.7.1 to v3.7.2. The study page itself continues to show a 403 error.SummaryDifference1%

- Check39 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page now displays a 403 Forbidden error, blocking access to the study record. This change represents an access restriction rather than modification of the study content visible on the page.SummaryDifference19%

- Check60 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, indicating a new release of the site's rendering/template. This change is a backend/version update and does not alter the displayed study details or other content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Recurrent Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.